Nuvation Bio (NUVB) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is NUVB's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

With nearly 40 months of follow-up, additional updated data from J201 study show the confirmed clinical benefit rate was 81.5% in patients with Grade 2 IDH1-mutant glioma Patients achieved a median target lesion reductio…

ACT Capital Partners L.P. bought a new position in Nuvation Bio Inc. (NYSE: NUVB) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 579,500 shares of the company's…

NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, P…

Nuvation Bio's Ibtrozi's roughly 50-month first-line durability means revenue depends on patients staying on therapy, not just new starts. Q3 Ibtrozi revenue rose 18% sequentially to $27.5 million, even with new starts f…

Nuvation Bio NYSE: NUVB reported $45 million in third-quarter 2026 revenue as U.S. sales of lung cancer treatment IBTROZI rose 18% from the previous quarter, even as the company said new patient starts declined across th…

Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript…

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.16 per share a year ago.…

Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 ma…

Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies Poster featuring Phase 2 results to be pres…

New sites in the UK, France, Sweden, Germany, Italy and Spain will add to the global footprint of the pivotal SIGMA study NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company …

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a c…

Shares of Nuvation Bio Inc. (NYSE: NUVB - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve analysts that are currently covering the company, Marketbeat.com reports. One equities research…

Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified Approval comes four months…

Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript…

Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroups Among pat…

Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Nuvation Bio Inc. (NYSE:NUVB) is a “pure spec.”…

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in ear…

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D.…

Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).…

Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma Pivotal Phase 3 SIGMA stud…

The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising ea…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

